Latest News for MAJI
Revised transaction expands NexTel's acquisition from JumpstartRx and NuevistraMed to Island 40 Group's broader growth platform, adding health services, pharmaceutical access, lab testing, institutional partnerships, and diversified revenue channels ORLANDO, Fla. , July 22, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc. ) (OTCID: MAJI), a clinical-stage biotechnology company focused on…
Revised transaction expands NexTel's acquisition from JumpstartRx and NuevistraMed to Island 40 Group's broader growth platform, adding health services.
NexTel Medical, OTCPK: MAJI, announced the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms
ORLANDO, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is excited to announce the commencement of the final stability phase for its inaugural line of commercial exosome products.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MAJI.
U.S. House Trading
No House trades found for MAJI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.